Rubraca previously received Breakthrough designation for the monotherapy treatment of certain advanced ovarian cancer patients
Rubraca is indicated as monotherapy for the treatment of adult patients with deleterious BRCA mutations (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer
